INM (InMed Pharmaceuticals) Intangible Assets: $1.50 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INM InMed Pharmaceuticals Inc INM
29 GF Score
Price $1.47
GF Value $0.92
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Intangible Assets?

InMed Pharmaceuticals INM -2.00% 29 Intangible Assets is $1.50 Mil as of Mar. 2026. GuruFocus rates INM with a GF Score™ of 29/100 and a GF Value™ of $0.92 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. InMed Pharmaceuticals's intangible assets for the quarter that ended in Mar. 2026 was $1.50 Mil.


InMed Pharmaceuticals  (NAS:INM) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


InMed Pharmaceuticals Intangible Assets Related Terms


InMed Pharmaceuticals Intangible Assets Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals Intangible Assets Chart

InMed Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Intangible Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.06 2.11 1.95 1.78 1.62

InMed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.66 1.62 1.58 1.54 1.50
INM
29GF Score
InMed Pharmaceuticals Inc INM
Intangible Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InMed Pharmaceuticals Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.

Frequently Asked Questions Learn more about Intangible Assets →
What does a Intangible Assets of $1.50 Mil mean?
InMed Pharmaceuticals (INM) has a Intangible Assets of $1.50 Mil as of Mar. 2026. Intangible assets include patents, goodwill and trade secrets. View historical data on InMed Pharmaceuticals and its competitors.
Is InMed Pharmaceuticals' Intangible Assets too high?
InMed Pharmaceuticals' current Intangible Assets is $1.50 Mil. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Intangible Assets compare to APUS and GELS?
InMed Pharmaceuticals' Intangible Assets of $1.50 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intangible Assets for a Drug Manufacturers company?
A good Intangible Assets depends on the Drug Manufacturers industry context. However, Intangible Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intangible Assets mean?
A high Intangible Assets can signal that a stock is expensive relative to its fundamentals. Intangible assets include patents, goodwill and trade secrets. View historical data on InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current Intangible Assets is $1.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, InMed Pharmaceuticals (INM) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.92, compared to a current price of $1.47 — trading 59.8% above its estimated fair value. The current Intangible Assets is $1.50 Mil. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intangible Assets calculated?
Intangible Assets is calculated from a company's financial statements. For InMed Pharmaceuticals (INM), the current Intangible Assets is $1.50 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InMed Pharmaceuticals (INM) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of $1.47 is trading 59.8% above its estimated GF Value™ of $0.92. GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for INM:

  • Intangible Assets: $1.50 Mil
  • GF Value™: $0.92 vs. price of $1.47 (59.8% above fair value)
  • GF Score™: 29/100 with 2 warning signs

No single metric tells the full story. See the INM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InMed Pharmaceuticals Business Description

Other Exchanges MWG:Germany
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score

Get the complete analysis for INM

Intangible Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.47
Price
$0.92
GF Value